Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest update is out from BioArctic AB Class B ( ($SE:BIOA.B) ).
BioArctic AB’s partner Eisai has received approval from the UK’s Medicines and Healthcare products Regulatory Agency for the intravenous maintenance dosing of Leqembi, a treatment for early Alzheimer’s disease. This approval allows patients to transition to a less frequent dosing schedule, potentially improving treatment adherence and quality of life for those affected by Alzheimer’s. The approval is based on successful Phase 3 clinical trial results and strengthens BioArctic and Eisai’s position in the Alzheimer’s treatment market.
The most recent analyst rating on ($SE:BIOA.B) stock is a Buy with a SEK328.00 price target. To see the full list of analyst forecasts on BioArctic AB Class B stock, see the SE:BIOA.B Stock Forecast page.
More about BioArctic AB Class B
BioArctic AB is a biopharmaceutical company focused on developing treatments for neurodegenerative diseases, particularly Alzheimer’s disease. The company collaborates with Eisai for the development and commercialization of lecanemab, an antibody therapy targeting amyloid-beta in Alzheimer’s patients.
Average Trading Volume: 308,327
Technical Sentiment Signal: Buy
Current Market Cap: SEK23.86B
For a thorough assessment of BIOA.B stock, go to TipRanks’ Stock Analysis page.